Finished product reference
Amyl Nitrite
Inhalant · Respiratory · 0.3 mL · 0.3 mL
- List code
- 1388
Indications
INDICATIONS AND USAGE: Amyl nitrite is indicated for the rapid relief of angina pectoris. Its effect appears within 30 seconds and lasts for approximately 3 to 5 minutes.
Dosage and administration (summary)
DOSAGE & ADMINISTRATION: With the patient in recumbent or seated position a capsule of amyl nitrite is held away from the face, crushed between the fingers, and held under the patient's nose. Two to six inhalations of the vapors from the capsule are usually sufficient to promptly produce therapeutic effects. Caution is recommended to avoid inhalation of excessive amounts of the drug when it is administered by someone other than the patient. If necessary, the dose may be repeated in 3 to 5 minutes.
Contraindications
CONTRAINDICATIONS: Since it may increase intraocular and intracranial pressures, amyl nitrite is contraindicated or should be used with great caution in patients with glaucoma, recent head trauma or cerebral hemorrhage. Amyl nitrite can cause harm to the fetus when it is administered to a pregnant woman because it significantly reduces systemic blood pressure and blood flow on the maternal side of the placenta.
Warnings and precautions
WARNINGS: Transient episodes of dizziness, weakness, or syncope or other signs of cerebral ischemia due to postural hypotension may develop following inhalation of amyl nitrite, particularly if the patient is standing immobile. To hasten recovery, measures which facilitate venous return such as head low posture, deep breathing and movement of extremities may be used.
Storage and supply
HOW SUPPLIED: JAMES ALEXANDER brand amyl nitrite is furnished in covered glass capsules. Each capsule contains 0.3 mL in boxes of 12. Capsule contents are FLAMMABLE and should be protected from light. Storage should be in a cold place. 2 o - 8 o C (36 o - 46 o F) The James Alexander Corporation Blairstown, New Jersey 07825. Rev.
Source: Amyl Nitrite (Amyl Nitrite) — US FDA prescribing information, 2019-02-05, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.